Quest Diagnostics, Inc (NYSE: DGX) has seen a decline in its stock price by -1.65 in relation to its previous close of 167.23. However, the company has experienced a 0.25% gain in its stock price over the last five trading sessions. zacks.com reported 2025-04-15 that Quest Diagnostics (DGX) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is It Worth Investing in Quest Diagnostics, Inc (NYSE: DGX) Right Now?
Quest Diagnostics, Inc (NYSE: DGX) has a price-to-earnings ratio that is above its average at 21.37x. The stock has a 36-month beta value of 0.53. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 1 as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for DGX is 111.03M, and at present, short sellers hold a 2.57% of that float. On April 17, 2025, the average trading volume of DGX was 1.29M shares.
DGX’s Market Performance
DGX’s stock has seen a 0.25% increase for the week, with a -4.63% drop in the past month and a 9.41% gain in the past quarter. The volatility ratio for the week is 2.65%, and the volatility levels for the past 30 days are at 2.92% for Quest Diagnostics, Inc The simple moving average for the past 20 days is -1.03% for DGX’s stock, with a 4.90% simple moving average for the past 200 days.
Analysts’ Opinion of DGX
Many brokerage firms have already submitted their reports for DGX stocks, with Redburn Atlantic repeating the rating for DGX by listing it as a “Buy.” The predicted price for DGX in the upcoming period, according to Redburn Atlantic is $195 based on the research report published on April 02, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see DGX reach a price target of $185. The rating they have provided for DGX stocks is “Neutral” according to the report published on March 04th, 2025.
Leerink Partners gave a rating of “Outperform” to DGX, setting the target price at $174 in the report published on January 06th of the current year.
DGX Trading at -2.48% from the 50-Day Moving Average
After a stumble in the market that brought DGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.05% of loss for the given period.
Volatility was left at 2.92%, however, over the last 30 days, the volatility rate increased by 2.65%, as shares sank -2.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.68% upper at present.
During the last 5 trading sessions, DGX rose by +0.25%, which changed the moving average for the period of 200-days by +20.16% in comparison to the 20-day moving average, which settled at $166.17. In addition, Quest Diagnostics, Inc saw 9.02% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DGX starting from Davis J. E., who sale 39,191 shares at the price of $168.46 back on Apr 02 ’25. After this action, Davis J. E. now owns 127,623 shares of Quest Diagnostics, Inc, valued at $6,602,074 using the latest closing price.
KUPPUSAMY KARTHIK, the SVP, Clinical Solutions of Quest Diagnostics, Inc, sale 2,555 shares at $170.00 during a trade that took place back on Apr 02 ’25, which means that KUPPUSAMY KARTHIK is holding 10,575 shares at $434,350 based on the most recent closing price.
Stock Fundamentals for DGX
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.32 for the gross margin
The net margin for Quest Diagnostics, Inc stands at 0.09. The total capital return value is set at 0.1. Equity return is now at value 13.24, with 5.74 for asset returns.
Based on Quest Diagnostics, Inc (DGX), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at 1.02. The interest coverage ratio of the stock is 6.11.
Currently, EBITDA for the company is 1.91 billion with net debt to EBITDA at 3.36. When we switch over and look at the enterprise to sales, we see a ratio of 2.51. The receivables turnover for the company is 7.57for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.10.
Conclusion
To sum up, Quest Diagnostics, Inc (DGX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
